Robeco Institutional Asset Management B.V. Buys 1,483 Shares of Amgen, Inc. (AMGN)

Robeco Institutional Asset Management B.V. lifted its stake in Amgen, Inc. (NASDAQ:AMGN) by 2.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 56,557 shares of the medical research company’s stock after purchasing an additional 1,483 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Amgen were worth $10,545,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of AMGN. TrimTabs Asset Management LLC grew its position in Amgen by 88.9% in the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after acquiring an additional 288 shares during the period. Baker Ellis Asset Management LLC purchased a new position in Amgen in the third quarter worth approximately $108,000. Jackson Grant Investment Advisers Inc. grew its position in Amgen by 0.8% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after acquiring an additional 5 shares during the period. Phocas Financial Corp. purchased a new position in Amgen in the second quarter worth approximately $110,000. Finally, Omnia Family Wealth LLC grew its position in Amgen by 25.3% in the second quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock worth $125,000 after acquiring an additional 147 shares during the period. 78.62% of the stock is owned by hedge funds and other institutional investors.

AMGN has been the subject of several analyst reports. Mizuho reiterated a “buy” rating and issued a $198.00 price objective (up from $183.00) on shares of Amgen in a research report on Thursday, September 28th. BMO Capital Markets reiterated a “hold” rating and issued a $198.00 price objective on shares of Amgen in a research report on Friday, October 20th. Jefferies Group reiterated a “buy” rating and issued a $200.00 price objective on shares of Amgen in a research report on Monday, September 25th. Royal Bank of Canada initiated coverage on Amgen in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $192.00 price objective for the company. Finally, Barclays increased their price objective on Amgen from $180.00 to $190.00 and gave the stock an “equal weight” rating in a research report on Friday, October 13th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $190.22.

In related news, Director Carbonnel Francois De sold 4,000 shares of Amgen stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total value of $694,440.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction on Monday, October 9th. The shares were sold at an average price of $185.95, for a total value of $283,573.75. The disclosure for this sale can be found here. Over the last quarter, insiders sold 8,575 shares of company stock valued at $1,509,339. 0.19% of the stock is currently owned by company insiders.

Amgen, Inc. (NASDAQ AMGN) opened at $176.14 on Tuesday. Amgen, Inc. has a 52-week low of $145.12 and a 52-week high of $191.10. The company has a market capitalization of $128,515.28, a price-to-earnings ratio of 14.07, a PEG ratio of 2.57 and a beta of 1.36. The company has a debt-to-equity ratio of 1.05, a quick ratio of 5.72 and a current ratio of 6.07.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, topping the consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The business had revenue of $5.77 billion during the quarter, compared to analyst estimates of $5.75 billion. During the same period last year, the business posted $3.02 earnings per share. The company’s quarterly revenue was down .7% on a year-over-year basis. equities research analysts predict that Amgen, Inc. will post 12.66 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Investors of record on Thursday, February 15th will be issued a $1.32 dividend. The ex-dividend date of this dividend is Wednesday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 dividend on an annualized basis and a yield of 3.00%. Amgen’s dividend payout ratio (DPR) is 41.63%.

Amgen declared that its board has initiated a share buyback plan on Wednesday, October 25th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s management believes its stock is undervalued.

TRADEMARK VIOLATION WARNING: This piece was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/12/19/robeco-institutional-asset-management-b-v-buys-1483-shares-of-amgen-inc-amgn.html.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply